Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic ...

Scientists believe this drug will be the first of a new wave of similar medications, ones that are both nonaddictive and ...

The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...

Last month, the Food and Drug Administration approved that molecule, now called Journavx, as a treatment for the sharp, short-lived “acute” pain usually felt after an accident or a surgery.

Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

Vertex Pharmaceuticals’ (VRTX) non-opioid pain drug Journavx was picked up by UnitedHealth’s (UNH) Optum on “Tier 3.” The insurer said, ...

The Nasdaq Composite Index ( ^IXIC -4.00%) is now squarely in correction territory. But stock market corrections have one key ...

RICHMOND, Va. (WRIC) — The U.S. Food and Drug Administration (FDA) has approved Journavx, the first opioid-free prescription drug for moderate to severe acute pain in more than 20 years.

But now the FDA has approved the first painkiller, Journavx, which works in a completely different way: not on the brain and spinal cord but on the nerves throughout the rest of the body.

RBC Capital notes that the clinical review documents associated with Sector Perform-rated Vertex Pharmaceuticals (VRTX)’ recent approval of ...